AMPH - CIK 0001297184
Amphastar Pharmaceuticals, Inc. trades as AMPH. In its fiscal 2025 annual report the company posted revenue of $719.89M, down 1.7% from the prior year and net income of $98.09M. This page tracks Amphastar Pharmaceuticals, Inc. through 924 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years Amphastar Pharmaceuticals, Inc.'s revenue grew from $255.16M to $719.89M, a compound annual growth rate of 12.2%. Net profit margin expanded from 3.8% to 13.6% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| Annual report to shareholders | ARS | 2026-04-13 |
| Proxy materials | DEFA14A | 2026-04-13 |
| Proxy statement | DEF 14A | 2026-04-13 |
| SCHEDULE 13G/A | - | 2026-03-26 |
| Insider trade | 4 | 2026-03-17 |
| Insider trade | 4 | 2026-03-17 |
The largest companies sharing Amphastar Pharmaceuticals, Inc.'s SEC industry classification (pharmaceutical preparations).
Amphastar Pharmaceuticals, Inc. reported revenue of $719.89M for fiscal year 2025, a decrease of 1.7% year over year.
Yes. Amphastar Pharmaceuticals, Inc. reported net income of $98.09M in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.